Skip to content
prognos-logo-light Prognos Health
Main Menu
  • Support
  • Client Login
  • Request Demo
  • prognosFACTOR™
    • Marketplace
  • Products
    • Life Sciences
      • Cohort Designer
      • Patient Journey
      • Physician Segmentation
      • Outcomes
      • Alerts
      • Omnichannel Marketing
    • Payers
      • Underwriting Risk Predictor
      • Risk Adjustment & Quality Analytics
  • Company
    • Careers
    • Events
    • News
    • Insights
  • Contact Us
Home Insights Our Pancreatic Cancer Analysis: How We Did It

Our Pancreatic Cancer Analysis: How We Did It

  • June 1, 2017
  • Posted in Disease Awareness

This post was last updated on December 2, 2019 at 9:51 pm

The Prognos Study Method

By Carol Smyth, MD & Brian Saindon

Background

About 80% of pancreatic cancers are found late, due to the lack of symptoms associated with the tumor until its late stages. Finding the tumor late results in poor survival rates. There is currently no specific blood test to screen for pancreatic cancer, and researchers around the world are working on identifying tests that would help to identify early pancreatic tumors. A 2009 study by Harsha et al found that over 1,000 genes can be overexpressed in pancreatic cancer, implying that there are many potential biomarkers waiting to be discovered (http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000046).

Method

Using the Prognos database of lab tests, which currently includes 9 billion tests from over 160 million patients, we identified patients at first diagnosis of pancreatic cancer via ICD-9 and ICD-10 codes in 2016. Tracking their lab results retrospectively, we looked back by 5 years to determine if there was a pattern in the “noise” of the lab tests, to see if there are potentially abnormal results in commonly conducted lab tests that may indicate an increased risk of pancreatic cancer on a population basis. This type of retrospective analysis has not been published to date in pancreatic cancer, to the best of our knowledge/research. Because there are many tests that were candidates for this analysis, we elected to focus on the following lab tests and results:

  • CA 19-9 and alkaline phosphatase because our previous research suggested that these were potential biomarkers (see http://abstracts.asco.org/156/AbstView_156_153453.html). In addition, CA 19-9 is the only biomarker approved by the FDA for pancreatic cancer (http://www.sciencedirect.com/science/article/pii/S1590865815006908).
  • Amylase – levels found to be high in less than 50% of patients with operable pancreatic cancer tumors (http://emedicine.medscape.com/article/280605-overview)
  • HbA1c and fasting glucose – due to the high rate of diabetes in patients with pancreatic cancer –  new onset diabetes is common in the year prior to diagnosis of pancreatic cancer
  • CA 125 – we included this test because previous studies suggest a rise in CA 125 is present up to 2 years prior to pancreatic cancer diagnosis (https://www.pancreaticcancer.org.uk/latest-news/2015/february/tumour-biomarkers-research-shows-promise-for-early-detection/)
  • Hemoglobin and platelets – these test results are often low in patients with pancreatic cancer

In the Prognos database, we identified 11,571 patients identified with ICD codes for pancreatic cancer in the calendar year 2016. Demographics of this patient group follow. We note that the group is approximately equal between genders, and that the majority of patients (>60%) are between the ages of 61 and 80 years old. These findings are in keeping with data published by the National Institutes of Health (https://seer.cancer.gov/statfacts/html/pancreas.html).

Cohort Descriptives

MeasureFrequency (n)(%)
Patient Gender
Male5,67249.02%
Female5,89850.97%
Unknown10.01%
Patient Age Distribution
Patient Age Group (years)
0-10100.09%
11-20110.10%
21-30450.39%
31-401701.47%
41-505294.57%
51-60201417.41%
61-70381432.96%
71-80329628.49%
81-90149712.94%
91-1001821.57%
>10020.02%
Unknown10.01%
Screen Shot 2017-06-01 at 3.35.33 PM

Patients with First Pancreatic Cancer Diagnosis in 2016 (n=11,571)

In the next blog, we will report on the analysis of our retrospective look at the common lab tests listed above, to see if there is a pattern in abnormal lab results over the 5-year period prior to diagnosis of pancreatic cancer in the 2016 patient cohort. Our hope is that identification of a pattern, if any, might lead to identification of a panel of common tests that might be used for screening for this lethal tumor.

Reading List:

  • http://emedicine.medscape.com/article/280605-overview
  • http://www.sciencedirect.com/science/article/pii/S1590865815006908
« Continuing the Search for Pancreatic Cancer Screening Tests
Pancreatic Cancer Screening: Initial Results »

Categories

  • AI
  • Alerts
  • Clinical
  • Disease Awareness
  • Lab Testing Insights
  • Lab Testing Trends
  • Omnichannel Marketing
  • Physician Segmentation
  • Prog Spotlight

Archives

Latest Tweets

Prognos HealthFollow

Prognos Health
prognosAIPrognos Health@prognosAI·
31 Dec

As we ring in the new year, there's so much to look forward to. We wish all of our clients, and partners a healthy, happy new year and are excited to continue innovating together in 2021 to positively impact care.

Reply on Twitter 1344647644669468672Retweet on Twitter 1344647644669468672Like on Twitter 13446476446694686722Twitter 1344647644669468672
prognosAIPrognos Health@prognosAI·
22 Dec

As this year comes to an end, our thoughts turn gratefully to our clients, partners, and the industry for an unwavering commitment to improving patient outcomes in the face of a global pandemic. We look forward with hope to innovating together in 2021 to positively impact care.

Reply on Twitter 1341473757291032582Retweet on Twitter 1341473757291032582Like on Twitter 13414737572910325821Twitter 1341473757291032582
Retweet on TwitterPrognos Health Retweeted
hikmapharmaHikma@hikmapharma·
21 Dec

In July we held a great discussion at our virtual #panel on digital health during the #COVID19 pandemic featuring panelists from @lemonaidhealth @prognosAI and @Click_Tx, some of @HikmaVentures' most exciting investments in digital health. #Top20of2020

Reply on Twitter 1340960230562287618Retweet on Twitter 13409602305622876182Like on Twitter 13409602305622876183Twitter 1340960230562287618
prognosAIPrognos Health@prognosAI·
16 Dec

2020 was filled with so many challenges, yet we’ve helped push the boundaries with our peers to accelerate change.

We ended the year on a high note and trust that 2021 will be brighter for us all!

https://prognoshealth.com/about-us/news/press-release/ends-innovative-year-with-award/

#Innovation #HealthTech #HealthAnalytics

Reply on Twitter 1339274462307475456Retweet on Twitter 1339274462307475456Like on Twitter 13392744623074754561Twitter 1339274462307475456
prognosAIPrognos Health@prognosAI·
8 Dec

Get the right message to the right #HCP at exactly the right time.

In his latest blog, Prognos Health's VP of Digital Solutions, Matt Apprendi, weighs in on achieving dynamic messaging through #OmnichannelMarketing that factors #ClinicalData.

https://prognoshealth.com/blog/laser-focused-and-perfectly-timed-omnichannel-pharma-marketing-that-factors-clinical-data/

Reply on Twitter 1336342925186306050Retweet on Twitter 13363429251863060501Like on Twitter 13363429251863060502Twitter 1336342925186306050
Load More...
  • prognosFACTOR™
    • Marketplace
  • Products
    • Life Sciences
    • Payers
  • Company
    • Insights
    • Careers
    • Events
    • News
  • LinkedIn
  • Twitter
  • YouTube
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Site Map
© Prognos Health, 2021. All Rights Reserved.

See What Decision Speed Looks Like in Action

To give you the best possible experience, this site uses cookies and by continuing to use the site you agree that we can save them on your device. For more details about cookies and their use, please see our Privacy Policy.